IntelGenx Technologies Corp.
IGX
Rang in Aktien
#28144
IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise... IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise focused on the creation and manufacturing of advanced oral thin film products. The company's diverse product pipeline encompasses various oral film formulations designed to address a wide spectrum of medical conditions. These include INT0008/2008, a Rizatriptan film for migraine management; INT0046/2018 for adult applications; INT0007/2006, an oral film targeting erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, intended for opioid addiction treatment; INT0010/2006, addressing neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, formulated for schizophrenia or bipolar I disorder; and INT0048/2020, developed for veterinary health. Additionally, IntelGenx is actively developing other candidates identified as INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established strategic partnerships, including a comprehensive licensing, development, and supply agreement with Tilray, Inc., alongside a development pact with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.
Aktienkurs
$0.17446996
Zuletzt synchronisiert: 2024-06-11
Marktkapitalisierung
$26.97M
Veränderung (1 Tag)
-0.57%
Veränderung (1 Jahr)
2.63%
Land
CA
Handel IntelGenx Technologies Corp. (IGX)
Kategorie
Healthcare
Operative Marge für IntelGenx Technologies Corp. (IGX)
Operative Marge zum October 2026 TTM: -913.47%
Laut den neuesten Finanzberichten und dem Aktienkurs von IntelGenx Technologies Corp. beträgt die aktuelle operative Marge (TTM) -913.47%. Am Ende des Jahres 2022 lag die operative Marge bei -990.84%.
Historie der operativen Marge von IntelGenx Technologies Corp. von 2003 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | -913.47% | 0.00% |
| 2023 | -913.47% | -7.81% |
| 2022 | -990.84% | 90.55% |
| 2021 | -520.00% | 28.17% |
| 2020 | -405.70% | -68.48% |
| 2019 | -1,287.06% | 160.90% |
| 2018 | -493.31% | 927.94% |
| 2017 | -47.99% | 155.40% |
| 2016 | -18.79% | -169.08% |
| 2015 | 27.20% | -125.35% |
| 2014 | -107.29% | -37.94% |
| 2013 | -172.89% | -5.33% |
| 2012 | -182.62% | -67.15% |
| 2011 | -555.91% | 147.59% |
| 2010 | -224.53% | 123.19% |
| 2009 | -100.60% | -55.18% |
| 2008 | -224.43% | 156.96% |
| 2007 | -87.34% | -69.72% |
| 2006 | -288.46% | 0.00% |
| 2005 | 0.00% | 0.00% |
| 2004 | 0.00% | 0.00% |
| 2003 | 0.00% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 38.59% | -100.04% |
US
|
|
| -149.01% | -99.84% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.03% |
NL
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.